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Abstract
Understanding the mechanism of infection control in elite controllers (EC) may shed light on the correlates of control of
disease progression in HIV infection. However, limitations have prevented a clear understanding of the mechanisms of elite
controlled infection, as these studies can only be performed at randomly selected late time points in infection, after control
is achieved, and the access to tissues is limited. We report that SIVagm infection is elite-controlled in rhesus macaques (RMs)
and therefore can be used as an animal model for EC HIV infection. A robust acute infection, with high levels of viral
replication and dramatic mucosal CD4+ T cell depletion, similar to pathogenic HIV-1/SIV infections of humans and RMs, was
followed by complete and durable control of SIVagm replication, defined as: undetectable VLs in blood and tissues
beginning 72 to 90 days postinoculation (pi) and continuing at least 4 years; seroreversion; progressive recovery of mucosal
CD4+ T cells, with complete recovery by 4 years pi; normal levels of T cell immune activation, proliferation, and apoptosis;
and no disease progression. This ‘‘functional cure’’ of SIVagm infection in RMs could be reverted after 4 years of control of
infection by depleting CD8 cells, which resulted in transient rebounds of VLs, thus suggesting that control may be at least in
part immune mediated. Viral control was independent of MHC, partial APOBEC restriction was not involved in SIVagm
control in RMs and Trim5 genotypes did not impact viral replication. This new animal model of EC lentiviral infection, in
which complete control can be predicted in all cases, permits research on the early events of infection in blood and tissues,
before the defining characteristics of EC are evident and when host factors are actively driving the infection towards the EC
status.
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Introduction
A minority of HIV-1-infected patients, defined as elite
controllers (ECs), demonstrate that effective control of viral
replication and disease progression is possible in the absence of
treatment [1]. Deciphering the mechanisms of natural infection
control in these patients is a critical step for designing successful
vaccines and is considered a priority in the field [2]. Research on
human ECs, however, is restricted to studies of the chronic
infection, samples collected at random time points, and limited
access to tissues, all precluding identification of early events
responsible for virus control. These shortcomings have likely
prevented a clear understanding of the immune mechanisms
driving infection towards elite-controlled status. An animal model
in which complete control of viral replication can be achieved in
all cases has strong potential to effectively complement EC
research in humans.
Pathogenic HIV and SIV infections of humans and RMs are
characterized by progression to AIDS in a variable time frame [3]
and are associated with: (i) massive, continuous viral replication
[4,5], with VL set-points being predictive for the time of
progression to AIDS [6]; (ii) continuous depletion of CD4+ T
cells in peripheral blood [7] which is more pronounced at mucosal
sites [8,9,10], and (iii) high levels of T cell immune activation [11],
the magnitude of which has been reported to be predictive of
disease progression [11]; (iv) only partial control of viral replication
through immune responses [12]. The interaction among these
factors cripples the immune system and eventually results in severe
immunodeficiency and death [7]. Antiretroviral (ARV) treatments
have improved survival, but they do not always provide complete
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control of viral replication [13] and are plagued by the issues of
ARV resistance and multiple side effects, which limit their long-
term use [14]. On the other hand, effective HIV/SIV vaccines are
not yet available to prevent the spread of HIV [15,16].
A fraction of HIV-infected patients (1–5%) are long-term
nonprogressors (LTNP), with ECs being a subset of long-term
nonprogressors. The main characteristics of LTNP infections are
(i) infection for more than 7 years; (ii) stable CD4+ T cell counts
greater than 600 cells/ml; (iii) low/undetectable levels of HIV in
the peripheral blood; (iv) no symptoms of HIV-induced disease; (v)
apparent control of viral replication through vigorous CD4+ and
CD8+ T cell responses against HIV suggesting, but not proving
that these cells may be causally related to virus control [1]. These
vigorous immune responses against HIV are characterized by
multifunctional, persistent CD8 responses, vigorous HIV-specific
interferon (IFN)-c and antiviral b-chemokines (including
RANTES), CD4+ T cell responses and macrophage inflammatory
protein MIP-1a and MIP-1b responses [17]; and (vi) lower
expression of PD-1 and CTLA-4 in LTNPs than in normal
progressors, with the ECs having the least expression [18]. All
these features occur in the absence of any ARV therapy. Similarly,
a minority of SIVmac-infected RMs is characterized by better
control of SIV infection, and these are also referred to as ECs
[19,20].
Some EC infections may either be intrinsic to the infecting viral
strain (i.e., nef-defective strains in humans or RMs), or host (i.e.,
heterozygosity for the CCR5D32 allele). However, the most
relevant category for understanding the mechanisms of protection
in EC infection is the one in which control is achieved through
effective host responses. There is a consistent association between
certain class I alleles and EC status, however the mechanistic role
of some of these alleles (i.e., HLA-B5701) in the control of HIV
remains an open question [1]. Conversely, viral control is
immune-mediated in human EC infections associated with B27
allele, or those associated with B*08 allele in RMs [1]. Finally,
about 40% of both human and RM ECs have no identified host
genetic traits associated with viral control [1]. Therefore, our
understanding of the mechanisms of EC infection would greatly
benefit from the possibility to study an EC infection before the
control is actually achieved, but when factors driving infection to
EC status are likely acting. The mechanisms underlying the
spontaneous control of SIV infection in ECs can provide clues for
the design of effective vaccine strategies or for the development of
a functional cure of HIV infection (defined by complete and
durable control of the HIV infection in the absence of virus
eradication).
Here we report the development of an animal model of elite
controlled infection in which control occurs in 100% of cases and
thus can be predicted at the stages of infection in which the virus is
still actively replicating. This animal model is based on RM
infection with SIVagm.sab, which is characterized by robust acute
viral replication and immune activation, massive acute mucosal
CD4+ T cell depletion, followed by complete control of viral
replication during the chronic stage, which results in complete
recovery of immunologic injuries inflicted during the acute
infection. We also report that complete control of SIVagm
infection in RMs can be reversed following CD8 depletion in vivo,
demonstrating persistence of the SIVagm in RMs and suggesting
control through immune responses. This new animal model of
‘‘super elite’’ controlled infection can be use to understand a
functional cure of HIV infection.
Results
SIVagm infection of RMs
Twelve RMs were intravenously infected with 100 TCID50 of
SIVagm.sab92018 directly derived from an acutely-infected AGM
[21]. Four of them were followed for more than 6 years post-
infection (p.i.). Two RMs were followed for 450 days p.i., while the
remaining RMs were serially sacrificed during acute and early
chronic infection. During the acute infection, RMs infected with
SIVagm showed significant lymphadenopathy. One RM devel-
oped a rash, while 6 of them experienced weight loss and fever.
However, after three months, SIVagm-infected RMs controlled
viral replication (see below) and none of them showed any clinical
or biological signs of disease progression during the follow-up.
SIVagm.sab replication is controlled in 100% of infected
RMs and control is not due to an impairment of viral
replication
SIVagm.sab showed active replication in RMs during primary
infection, with peak plasma VLs (107–109 copies/ml) occurring by
day 10 p.i. (Figure 1a). These VL levels are in the range of those
reported for pathogenic SIVmac and HIV-1 infections in RMs
and humans, respectively. In contrast to the high viral replication
during the acute infection, the postpeak SIVagm.sab VLs
continuously declined in RMs until VLs became undetectable,
by days 72–98 p.i. and remained so during the follow-up
(Figure 1a). SIVagm RNA VL dynamics in the intestine generally
paralleled that observed in plasma (Figure 1b). The high levels of
viral replication in the intestine during the acute SIVagm infection
of RMs were confirmed by in situ hybridization (Figure S1). Blips of
very low levels of viral replication could be documented at mucosal
sites during the first stages of chronic infection, up to day 400 p.i.
(Figure 1b). Thus, SIVagm.sab replication in RMs during chronic
infection is clearly different from both the replication patterns
described in pathogenic SIV/HIV infections (where set-point VLs
are established that have predictive values for the duration of
disease progression, and increases in VLs occur with disease
progression) and in nonpathogenic natural infections of African
NHPs (where set-point VLs are maintained indefinitely) [22,23].
We concluded that (i) the undetectable VLs that last up to 4
years define 100% of SIVagm-infected RMs as ECs; and (ii)
Author Summary
A small proportion of HIV-infected patients control viral
replication and disease progression in the absence of any
antiretroviral treatment. Understanding the mechanisms of
viral control in these elite controllers may help to identify
new therapeutic approaches in order to control HIV
infection. However, elite controllers are identified AFTER
control is established, therefore it is difficult to identify the
virus and host factors that drive the infection to the
controlled status. We identified an animal model (the
rhesus macaque infection with SIVagm) in which, after
massive acute viral replication and CD4+ T cell depletion,
SIV infection is controlled in 100% of cases during chronic
infection. This ‘‘functional cure’’ of SIVagm infection in
rhesus macaques results in a complete immune restoration
after four years and can be reverted by depleting the
cellular immune responses in vivo. An animal model of
elite controlled lentiviral infection in which complete
control can be predicted in all cases permits research on
the early events of infection when host factors are actively
driving the infection towards the controlled status to
understand the pathogenesis of HIV/SIV infections and
design of new approaches for controlling HIV infection.
Animal Model for Elite Controlled SIV Infection
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SIVagm.sab replication is not restricted in RMs and its control
during the late stages of SIV infection is not due to the inability of
the virus to replicate in RMs.
The complete control of SIVagm replication in chronically-
infected RMs was further suggested by the dynamics of anti-gp41
SIVagm antibodies in RMs, as detected by a specific SIVagm.sab
peptide mapping the immunodominant epitope of gp41 using an
in-house ELISA [21]. Seroconversion occurred in all animals by
day 21 p.i. (Figure 2a). With the complete control of viral
replication during chronic infection, the animals seroreverted
starting from day 360 p.i. (Figure 2a). Anti-SIVagm.sab neutral-
izing antibodies showed a similar dynamics (Figure 2b), also
supporting the control of viral replication. The levels of anti-
SIVagm.sab92018 in RMs were not substantially different from
those observed in experimentally-infected AGMs [24]. Both the
magnitude and the dynamics of NAbs suggest that humoral
Figure 1. Viral replication during acute and chronic SIVagm infection of RMs. (a) Plasma viral load quantification showed high levels of viral
replication during acute infection followed by complete control of viremia, with undetectable plasma viral loads, starting from days 72–98 p.i. on. (b)
the overall pattern of SIVagm replication in the intestine generally paralleled that of plasma viral load, but control of viral replication was achieved at
later time points (after day 132 p.i.). The detection limit of the assay was 102 copies/ml of plasma and 10 copies per 106 cells.
doi:10.1371/journal.ppat.1002170.g001
Figure 2. Control of SIVagm replication in RMs was confirmed by seroreversion of anti-SIVagm binding and neutralizing
antibodies. (a) Dynamics of anti-gp41 antibody titers in SIVagm-infected RMs by SIVagm.sab-specific ELISA. All animals seroconverted between days
14–21 post-infection. Antibody titers reached the highest levels by day 98 p.i., then continuously declined as VLs were controlled. (b) Neutralizing
antibodies against SIVagm.sab92018 also vane with the control of viral replication.
doi:10.1371/journal.ppat.1002170.g002
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responses are peripheral to the control of SIVagm.sab in rhesus
macaques.
Finally, nested PCR for different SIV genomic regions on RNA
and DNA from serial samples of plasma, PBMCs, LNs or intestinal
lymphocytes collected during chronic infection (days 720, 1080
and 1260 p.i.) were all negative, suggesting the complete control of
SIVagm replication by RMs. However, the negative PCRs on
these late time point samples may be due to the fact that the PCRs
were carried out on a limited number of cells (in general, less than
56105 cells per assay), which might have been insufficient for the
detection of very low amounts of SIVagm.
Control of SIVagm infection in RMs does not result from a
limited viral replication in tissues during acute infection
A viral replication restricted to certain anatomical sites was
reported in the past to occur during SHIV infection [25]. In such a
pathogenic scenario, CXCR4-tropic SHIVs would predominantly
replicate in lymphoid tissues resulting in a very active acute
infection followed by the control of viral replication during the
chronic stage of infection [26]. To assess the extent of SIVagm.sab
replication in RMs, we performed serial necropsies at the peak of
viral replication (Days 9 and 10 p.i.), at the set-point (Days 35 and
42 p.i.) and during early controlled infection (Day 180 p.i.). Plasma
viral loads are presented in Figure 3a. SIVagm.sab was then
quantified on snap frozen tissue fragments collected at the
necropsy. RNaseP was used to quantify the number of cells in
each tissue. As shown in Figure 3b, during acute infection the virus
was present at very high levels in both lymphoid and nonlymphoid
tissues. Viral loads dropped by 3–4 logs at the set point (Figure 3b),
while during the chronic infection viral replication was generally
controlled in all the analyzed tissues, with very low blips being
observed in the mesenteric lymph node, rectum and testis in RM
CM44 and in the submandibular LN and colon in RM CE26
(Figure 3b). These very low levels of residual tissue viral replication
may explain why the residual increased immune activation may
persist after the control of plasma VL below detection limits in
SIVagm-infected RMs. Similar widespread SIVmac replication
was previously reported in RMs, albeit in a more limited number
of tissues [27,28].
The generalized, massive acute viral replication in SIVagm-
infected RMs demonstrates that control of viral replication during
chronic infection is not due to a preferential viral replication to
certain anatomical sites.
The control of SIVagm.sab replication in RMs does not
appear to be due to specific MHC profiles that may drive
infection to EC status
All SIVagm-infected RMs were MHC-typed and no correlation
between a given MHC type and control of SIVagm replication
could be found for RMs (data not shown). With the exception of
RM V492, which harbored a B*17 allele, none of the remaining
RMs harbored alleles usually associated with control of SIVmac
infection (A*01, B*08 or B*17) [19,20]. Mamu-A*02 allele, a
relatively frequent allele in RMs which is not associated with SIV
control, was present in 60% of our RMs. We therefore concluded
that the control of SIVagm replication in RMs is independent of
MHC types.
Figure 3. Measurement of SIV RNA in serially sacrificed RMs infected with SIVagm.sab. Six rhesus macaques were included in this study
and were serially sacrificed at the peak of viral replication (day 9 pi-RMDJ52 and D10 pi-RMCV08), at the set-point (day 35 pi-RMDJ73 and D42 pi-
RMEK15) and during chronic infection (D180pi), when infection is controlled (RMCM48 and RMCE26). (a) Quantification of plasma viral load showed
that all these RMs replicated the virus at high levels during acute infection and that the virus load was controlled below detection limits in the RMs
euthanized during chronic infection. (b) Quantitative RT–PCR analysis of SIVagm.sab RNA from over 30 tissues obtained at necropsy demonstrated
that virus control is not due to a restriction of virus replication to a limited number of anatomical sites.
doi:10.1371/journal.ppat.1002170.g003
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Control of SIVagm.sab is not due to an inability of the
virus to efficiently infect CD4+ T cells in different tissue
compartments
CD4+ T cell dynamics were investigated in peripheral blood,
lymph nodes (LNs) and intestine of SIVagm.sab-infected RMs
using both flow cytometry and immunohistochemistry (IHC). The
dynamics of blood CD4+ T cells were consistent with the pattern
of viral replication. Thus, the high SIV VLs observed during acute
infection were accompanied by a moderate (<30–40%) but
significant (p = 0.03) peripheral CD4+ T cell depletion after the VL
peak (Figure 4a). During the chronic phase, peripheral CD4+ T
counts rebounded to preinfection levels starting from day 200 p.i.
on (Figure 4a), in contrast to pathogenic infections. In the LNs,
CD4+ T cell depletion was also moderate and persisted up to 200
days p.i.; both flow cytometry (Figure 4b) and IHC on serial LN
samples (data not shown) showed complete restoration at late time
points.
A dramatic (up to 95%) acute depletion of CD4+ T cells
occurred by days 14–28 p.i. at the immune effector sites in the
lamina propria of the intestine (Figure 4c). IHC on serial samples
confirmed marked gut-associated lymphoid tissue (GALT) CD4+
T cell loss during primary SIVagm infection of RMs (Figure S2).
During chronic SIVagm infection, after the control of SIVagm.sab
replication, a gradual immune restoration was observed in RMs
(Figure 4c). IHC confirmed this gradual GALT CD4+ T cell
recovery (data not shown), which resulted in a complete
restoration of the mucosal CD4+ T cells after 4 years p.i. The
mucosal CD4+ T cell recovery was incomplete in SIVagm-infected
RMs that were followed for 450 days p.i. However, a similar trend
for mucosal CD4+ T cell recovery was observed in these animals
(Figure 4c). This pattern of CD4+ T cell changes observed in
SIVagm-infected RMs is unprecedented and significantly differs
from SIVsmm/mac-infected RMs that show continuous, persistent
loss of mucosal CD4+ T cells during chronic infection and
progression to AIDS [25]. Therefore, we concluded that (i) the
outcome of SIVagm infection of RMs is not due to its inability to
infect mucosal CD4+ T cells; (ii) GALT CD4+ T cell depletion
during acute infection of SIVagm-infected RMs was of the same
order of magnitude as the CD4+ T cell depletion that usually
occurs in pathogenic SIVsmm infections of RMs, thus not being
predictive for clinical outcome of SIV infection; (iii) the complete
control of SIVagm infection in RMs resulted in a slow but
complete restoration of CD4+ T cells.
Control of SIVagm replication in RMs does not result
from a peculiar in vivo biology of the virus
We then addressed the question of whether or not the control of
SIVagm.sab infection in RMs is due to a particular biology of the
virus that may restrict infection to particular CD4+ T cell subsets.
We have previously characterized SIVagm.sab and showed no
significant deletion in any of the accessory genes (particularly the
nef gene) that might be associated with impaired viral replication
[29,30]. Moreover, in numerous comparative pathogenesis studies
in AGMs and pigtailed macaques, we have shown robust levels of
in vivo replication of SIVagm.sab, as well as progression to AIDS in
pigtailed macaques [21,29,31] [Pandrea, unpublished].
We have previously reported, based on in vitro studies, that
SIVagm.sab92018 has the ability to use CXCR4 in addition to
CCR5 as a coreceptor for virus entry [29]. Note, however, that the
in vivo dynamics of SIVagm.sab infection in its natural host, the
AGM, is very similar to other infections produced by CCR5-tropic
SIVs that infect vervets, SMs and mandrills [32,33]. We therefore
investigated whether or not the in vivo biology of SIVagm in RMs
Figure 4. Changes in CD4+ T cells in SIVagm-infected RMs.
Acute viral replication resulted in a significant depletion of CD4+ T cells
in blood (a), lymph nodes (b) and intestine (c), which was massive at
mucosal sites. With the control of viral replication, complete recovery of
CD4+ T cell was observed during the follow-up.
doi:10.1371/journal.ppat.1002170.g004
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has particularities that may explain virus control and established
multiple lines of evidence that SIVagm.sab is CCR5 tropic in vivo:
(i) during acute infection of RMs, SIVagm.sab depleted up to 95–
99% of CD4+ T cells in the intestine (Figure 4c), in agreement with
the high CCR5 expression on CD4+ T cells at the mucosal sites.
Such a massive depletion clearly involved all the CD4+ T cell
subsets (data not shown). This pattern was similar to all other
CCR5-tropic SIVs and HIVs [25] and differed from the in vivo
pathogenicity of the CXCR4-tropic SHIVs, which show only
minimal depletion of mucosal CD4+ T cells [25]. (ii) In vivo,
SIVagm.sab depleted CCR5+CD4+ T cells and not
CXCR4+CD4+ T cells in macaques, suggesting the in vivo usage
of CCR5 as the coreceptor of SIVagm in RMs (Figure 5). In
addition, phenotyping of the SIVagm-infected cells in RMs also
showed that the in vivo SIVagm.sab replicated predominantly in
lymphocytes in intestine and LNs (Figure S3), very similar to
SIVmac [34]. In addition, the effector memory CD4+ T cell subset
was the cell population most depleted during the SIVagm infection
in RMs (Figure 5). We therefore concluded that SIVagm has an in
vivo biology that is similar to pathogenic lentiviruses able to induce
AIDS in NHPs.
We further confirmed these results by assessing the coreceptor
usage of the replicating SIVagm during the acute stage of infection
(day 10 p.i.) of RMs by testing plasma collected at the peak of viral
replication in RMs and comparing it to that observed for the virus
in the supernatant of RM PBMC cultures. SIVmac239 (R5-tropic)
and SHIV 162P3 (R5-tropic) were used as controls. This
experiment confirmed our previous results [29], and showed that
in vitro passaged SIVagm.sab is dual tropic (CCR5 and CXCR4),
similar to other SIVagm.sab strains (Figure S4). However,
SIVagm.sab from the plasma during acute infection (i.e., the
replicating virus) used only CCR5 as a coreceptor (Figure S4).
Therefore, these experiments demonstrate that the control of
SIVagm.sab in RMs is not due to a particular biology of the virus.
CD4+ T cell depletion occurred in SIVagm-infected RMs
through the same mechanisms as in pathogenic SIVmac
infection of RMs
One of the major differences between pathogenic and
nonpathogenic SIV infections relies on the mechanisms of CD4+
T cell depletion. In pathogenic infection, destruction occurs
through direct killing and indirect mechanisms, such as bystander
apoptosis [34]. Conversely, in nonpathogenic infections, the levels
of apoptosis do not significantly change during SIV infection [32].
We therefore assessed the mechanisms of CD4+ T cell destruction
in SIVagm-infected RMs by flow cytometry and IHC. Flow
cytometric analysis revealed increases of both necrosis and
apoptosis of GALT CD4+ T cells that paralleled viral replication
(Figure 6a). These results were confirmed by IHC for active
caspase-3 that showed increased apoptosis in both intestine and
LNs during acute SIVagm.sab infection (Figure 6b, middle panels)
compared to preinfection levels (Figure 6b, upper panels) and late
chronic infection (Figure 6b, lower panels). These increases in
apoptosis persisted after the plasma VLs became undetectable,
suggesting bystander apoptosis as a significant contributor to the
Figure 5. CD4+ T cell depletion pattern in SIVagm-infected macaques. PBMCs were examined by polychromatic flow-cytometry for their
correlated expression of cell surface CD3 vs CD4 vs CCR5 vs CD28 vs CD95 vs CXCR4 both before and 28 days after infection. Note the striking
depletion of CD4+ memory T cells (CD95+), and within the memory population, the effector memory (CD28negCD95+) and the CCR5-expressing
subsets. Meanwhile, CXCR4-expressing cells are well maintained during acute SIVagm.sab infection in RMs. This pattern is identical to the one
reported by Picker et al., for CCR5 tropic viruses [25].
doi:10.1371/journal.ppat.1002170.g005
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delay of several months in the restoration of CD4+ T cells after
viral control (Figure 3). Therefore we concluded that the
mechanism of CD4+ T cell destruction during acute SIVagm
infection of RMs was through both direct viral lysis and bystander
apoptosis, being similar to that reported for pathogenic SIVmac-
infected RMs [34]. Moreover, the correlation between the
normalization of bystander apoptosis and mucosal CD4+ T cell
recovery during the chronic stage of SIVagm.sab infection in RMs
suggests that the main mechanism of CD4+ T cell destruction
during the chronic infection is through bystander apoptosis.
The complete control of SIVagm replication in RMs
resulted in the restoration of the mucosal immunologic
barrier
Microbial translocation from the intestinal lumen to the general
circulation may result in increased immune activation and
contribute to the CD4+ T cell depletion. This event occurs as a
result of damage to the mucosa during SIV/HIV infection. During
the acute SIVagm infection of RMs, we observed both high viral
replication and increases in apoptosis levels of both CD4+ T cells
and intestinal epithelial cells (Figure 6b), we assessed the dynamics
of microbial translocation in RMs by measuring the levels of
sCD14 [35]. sCD14 testing was preferred over the LPS testing
because it was reported to be a robust test to measure microbial
tranlocation [35], while plasma LPS measurements are less
reliable (they show 25% interassay variability) [35]. Also, serum
LPS levels depend on other factors (i.e., levels of LPS binding,
degradation).
The massive SIVagm replication during acute infection of RMs
led to high levels of immune activation and increases in apoptosis
resulted in damage to the intestinal barrier as illustrated by the
transient increase in plasma sCD14 (Figure 7). However, after the
onset of control of viral replication and normalization of immune
activation and apoptosis, sCD14 levels returned to baseline values
which were maintained during the follow-up (Figure 7). Therefore,
we concluded that if SIV replication is completely controlled, the
integrity of the mucosal barrier can be restored and the immune
system, although ‘‘crippled’’ by the acute infection, does not
progress to ‘‘exhaustion’’ during the chronic phase, as in
pathogenic HIV/SIV infections [7].
The complete control of SIVagm replication is associated
with control of T cell immune activation and proliferation
in SIVagm-infected RMs
During the acute SIVagm infection of RMs, increases in
immune activation (HLA-DR) and cell proliferation (Ki-67) were
observed for both CD4+ and CD8+ T cells (Figure 8). These levels
started to decrease after the peak of infection, but immune
activation and proliferation remained increased for approx. 200
days p.i., paralleling the increased levels of apoptosis (Figure 6).
Indeed, the decrease in apoptosis levels and proliferation during
this period were highly correlated (r = 0.87, p= 0.016). Overall,
both markers of proliferation and apoptosis were highly correlated
with CD4+ T cell levels in GALT (p,0.0001). Later on, both T
cell activation/proliferation (Figure 8) and apoptosis (Figure 6)
returned to baseline, which corresponded to significant GALT
CD4+ T cell restoration (Figure 2). These profiles correlated with
those of sCD14 and differed from those observed in pathogenic
infections, in which continuous viral replication is associated with
persistent damage of intestinal mucosa resulting in continuous and
rampant immune activation and cell proliferation, which are
associated with disease progression [25]. Therefore, we concluded
that (i) the complete control of SIVagm viral replication resulted in
normalization of T cell immune activation, proliferation, pro-
grammed cell death and subsequent restoration of CD4+ T cells to
normal levels; (ii) the control of immune activation, cell
proliferation and apoptosis occurred after plasma VLs became
undetectable and explains delays observed in CD4+ T cell
restoration; (iii) normalization of T cell immune activation,
proliferation and apoptosis provide further evidence for the
complete control of SIVagm replication in RMs.
Control of SIVagm.sab replication in RMs does not
appear to be due to host restriction factors
Lentiviruses can infect new host species [32] in spite of the
formidable barriers imposed by host defenses. In these cases, a
transient viremia may be due to host immune defenses. However,
host restriction factors (i.e., APOBEC) might play a role in the
control of cross-species transmitted infection through catastrophic
Figure 7. Longitudinal analysis of the microbial translocation
in 5 SIVagm-infected RMs. Only a transient increase in plasma levels
of sCD14 was observed in SIVagm-infected RMs. Then, with the control
of apoptosis, the sCD14 levels returned to baseline.
doi:10.1371/journal.ppat.1002170.g007
Figure 6. Dynamics of CD4+ T cell apoptosis during acute and controlled SIVagm.sab infection of rhesus macaques. (a) Flow
cytometric assessment of apoptotic and necrotic cells in the gut showed significant increases of both apoptotic and necrotic cells in association with
the high levels of acute viral replication. Increases in apoptosis levels persisted longer than SIVagm viremia being probably responsible for the delays
in CD4+ T cell restoration. (b) Immunohistochemistry for activated caspase-3. There is a significant increase in apoptosis during the acute infection in
both intestine and LNs (middle panels) in SIVagm-infected RMs compared to the pre-inoculation samples from the same sites (upper panels). During
late chronic infection the number of activated caspase-3 positive cells decrease in intestine and LNs (lower panels) to levels similar to the pre-
infection ones, confirming the flow cytometry data. Note that, during acute SIVagm infection, both lamina propria and intestinal epithelia of RMs
show an increased number of apoptotic cells (middle panel, left) thus explaining the transient bacterial translocation.
doi:10.1371/journal.ppat.1002170.g006
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GA mutations during reverse transcription that either results in a
nonfunctional cDNA or in a cDNA that is targeted for
degradation [36]. Therefore, we have investigated the possibility
that cross-species transmission of SIVagm.sab to RMs was
controlled by a partial host restriction through APOBEC. We
have sequenced env of SIVagm.sab sampled at different time points
from RMs and compared sequence variability to that observed in
SIVagm-infected AGMs. Results are shown in Figure S5. No
significant accumulation of GA hypermutations was observed in
SIVagm-infected RMs. We also evaluated the accumulation of
synonymous (ds) versus nonsynonymous (dn) substitutions in
SIVagm strains infecting RMs and AGMs. Evaluation of the ds/
dn ratio gives an indication of the type of selection pressure that
contributes to the evolution of viral sequences. A majority of
synonymous mutations (ds/dn.1) would indicate the predomi-
nance of a purifying type of selection, which is associated with a
preferential elimination of viruses with variant amino acids.
Conversely, a majority of nonsynonymous mutations (ds/dn,1)
reflects the predominance of a diversifying type of selection. A
comparison between ds/dn ratios showed no significant differences
between SIVagm-infected RMs (average ds/dn ratio: 7.1677;
range: 2.13–10.78) and SIVagm-infected AGMs (average ds/dn
ratio: 6.89; range: 1.98–9.96).
It was recently reported that TRIM5 suppresses cross-species
transmission of SIV and that TRIM5 genotype correlate with 100-
fold to 1,000-fold differences in viral replication levels [37].
Therefore, we investigated the impact of TRIM5 on the levels of
SIVagm.sab replication in RMs as a potential host restriction
mechanism of viral replication and we report that no such
correlation could be established. SIVagm-infected RMs belonged
to different TRIM5 genotypes, such as: TFP/TFP (P373); TFP/Q
(BA38; EK15); TFP/CypA (DJ52; CV08; DG50) and Q/CypA
(DD16). No difference in viral replication could be observed
between these groups.
Finally, we performed an in vitro study of SIVagm.sab92018
replication in RM cells. As controls, we used SIVagm.sab
replication in African green monkey PBMCs, as well as the highly
pathogenic SIVmac239 on RM PBMCs. Our results showed that
Figure 8. Dynamics of peripheral T cell activation, as assessed by changes in HLA-DR and Ki-67 expression on CD4+ and CD8+ T cells
in SIVagm-infected RMs. SIVagm infection of RMs induced transient levels of activation and proliferation of both CD3+ CD4+ and CD3+ CD8+ T
cells. After the control of viral replication in tissues, both activation and proliferation markers returned to preinfection levels.
doi:10.1371/journal.ppat.1002170.g008
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SIVagm.sab replicated in peripheral blood mononuclear cells
(PBMC) from RMs at similar levels as in AGM PBMCs (Figure 9),
in agreement with previous reports [38]. There was a robust and
persistent SIVagm in vitro replication in both CD4+ T cells and
monocyte-derived macrophages (MDMs) from AGMs, RMs and
humans (data not shown). Persistent SIVagm replication on RM
PBMCs, (Figure 9) suggests that the virus is not controlled by host
restriction factors.
Elite controlled SIVagm infection in RMs can be reverted
by depletion of CD8+ cells, which suggest involvement of
immune responses in the EC of viral replication
To ascertain if the lack of detectable VLs in SIVagm-infected
RMs is due to control by cellular immune responses, we treated
three long-term infected RMs with a single 50 mg/kg dose of cM-
T807 anti-CD8 depleting antibody. Two EC SIVagm-infected
RMs were sampled according to the same schedule and were used
as controls. CD8 depletion was successful for 28–42 days in the
periphery in all treated RMs (Figure 10a) and induced
downregulation of CD8+ T cells in the intestine (not shown).
Prior to CD8 depletion, viral replication was undetectable for 4
years (Figures 1 and 2). Postdepletion, a rebound in plasma VLs
was observed in 3/3 RMs (BA38, P373 and V492) (Figure 10b). By
day 42 post-cM-T807 administration, VLs became undetectable
in all RMs. VL control was coincidental with the rebound of CD8+
T cells (Figure 10a and b). Viral replication was accompanied by
depletion of CD4+ T cells in blood and in intestine (Figure 10b).
Interestingly, peripheral CD4+ T cell depletion was abrupt and
preceded the rebound of viral replication (Figure 10b), probably as
a consequence of the use of an anti-CD8a depleting antibody [39].
Indeed, a fraction of CD4+ T cells that also express the CD8a
molecule and may be therefore targeted by the depleting antibody.
At the mucosal site, although a significant number of intestinal
CD4+ T cells express the CD8 molecule, the anti-CD8 antibody
Figure 9. In vitro SIVagm replication on PBMCs from rhesus
macaques and AGMs. In vitro replication was tested on PBMCs
originating from 3 RMs (DV11, DF93 and DD51). Each experiment was
performed in triplicate. In vitro growth curves (6standard deviation) are
shown.
doi:10.1371/journal.ppat.1002170.g009
Figure 10. Administration of cM-T807 depleting antibody
resulted in a rebound of plasma VLs in all three SIVagm-
infected RMs. (a) cM-T807 successfully depleted anti-CD8 cells in
periphery and resulted in a rebound of viral replication; (b) transient
CD4+ T cell depletion in periphery and intestine was observed following
the rebound of viral replication (c) increased in CD4+ T cell activation
and proliferation (as assessed by the study of –DR and Ki-67) were
observed, that lasted longer than the rebound in viral replication. CD8
depleted animals: BA38 (m); V492 (&); P373 (N).
doi:10.1371/journal.ppat.1002170.g010
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only downregulate CD8+ cells [39] and therefore mucosal CD4+ T
cell depletion paralleled the rebound of viral replication
(Figure 10b). In all three RMs, the administration of anti-CD8
antibody significantly increased CD4+ T cell activation, as defined
by -DR expression in periphery (Figure 10c) and intestine (not
shown) as well as CD4+ T cell proliferation, as defined by Ki-67
expression (Figures 10c). Note that the dynamics of VLs correlated
with the CD8+ T cell depletion and rebound and not with
increased CD4+ T cell activation and proliferation, which
persisted longer than CD8+ T cell depletion. Therefore, we
concluded that SIVagm replication appears to be controlled in
RMs at least in part by cellular immune responses.
Discussion
In this study, we showed that rhesus macaque infection with
SIVagm results in an infection pattern that models that of elite
controlled HIV infection in 100% of cases. Acute SIVagm
infection of RMs was similar to pathogenic infection, being
characterized by robust acute viral replication and massive
mucosal CD4+ T cell depletion. However, during the chronic
stage of infection, SIVagm was eventually completely controlled in
all RMs in blood and tissues. Inflammation and apoptosis were
resolved at mucosal sites, microbial translocation was controlled,
immune activation returned to baseline levels and mucosal CD4+
T cells were completely restored in RMs infected with SIVagm.
We also report that SIVagm elite controlled infection in RMs
could be reverted by experimental depletion of CD8+ cells,
suggesting that, similar to HIV-infected human elite controllers,
cellular immune responses are involved in the control of SIVagm
infection in RMs. Therefore, this new animal model of elite
controlled infection may be used to model the viral and host
factors involved in the achievement of long-term control of HIV
replication in the absence of antiretroviral therapy, i.e., the
‘‘functional cure’’ of HIV infection.
The use of this new animal model for SIV infection allowed us
to address some of the most important open questions of SIV/HIV
pathogenesis, which may have immediate implication for the
management of HIV-infected patients. First, in agreement with
our previous reports [31,40,41], our model of functional cure for
HIV infection demonstrates that acute mucosal CD4+ T cell
depletion has no prognostic value for the chronic outcome of
infection. Second, we report that residual apoptosis and immune
activation in subjects with undetectable plasma VLs are due to an
incomplete control of viral replication. In SIVagm-infected RMs,
low levels of viral replication persisted in tissues several months
after plasma VL became undetectable and prevented the control
of the apoptosis, microbial translocation and immune activation,
hence the immune restoration was quasi inexistent during this
time. Conversely, after the achievement of the complete control of
virus replication in tissues, apoptosis and immune activation were
resolved and normalization of these parameters was followed
complete restoration of the mucosal CD4+ T cells. These findings
suggest that in human ECs, as well as in patients treated with
HAART, incomplete immune restoration and persistent elevated
levels of immune activation which are observed in spite of
undetectable plasma VLs may be due to very low levels of residual
viral replication in tissues [42,43], calling for a therapeutic control
of viral reservoirs to restore and preserve the levels of CD4+ T cells
[44]. Furthermore, our model demonstrates that only the long-
term normalization of immune activation and inflammation may
lead to complete immune restoration in HIV-infected patients. In
our study, mucosal CD4+ T cells restoration only occurred four
years after the return of apoptosis and immune activation to near
baseline levels. Finally, our study showed that sustained complete
control of viral replication may result in seroreversion. Serorever-
sion was not reported in ECs, but occurred in a patient that
achieved the functional cure after being treated with allogeneic
CCR5D32/D32 stem cell transplantation for relapsed acute
myeloid leukemia (the ‘‘Berlin patient’’) [45]. As for the
SIVagm-infected RMs, the functional cure in this patient was
characterized by lack of disease progression for 45 months in the
absence of antiretroviral therapy, CD4+ T cell reconstitution to
normal values in peripheral blood and at mucosal sites,
undetectable HIV RNA and DNA in plasma and tissues and
seroreversion [45]. These striking similarities between RMs
infected with SIVagm and the ‘‘Berlin patient’’, which is currently
the standard for the functional cure of HIV infection, reinforce the
value of our new animal model.
In the currently available animal models of EC infection,
control is only achieved in a fraction of monkeys or it is due to
significant attenuation of the virus. Thus, viral replication of
attenuated strains of SIVmac, such as D-nef or D-3 strains [46] is
impaired in all phases of infection by significant alterations in virus
structure. This pattern is in sharp contrast with the majority of the
EC infection in humans in which the viruses are replication-
competent without major deletions [47]. Second, suppression of
viremia in pathogenic macaque infections through highly active
antiretroviral treatments [48] does not fulfill the definition criteria
for EC infection, as the animals are ARV-treated and low levels of
viral replication, immune activation and incomplete immune
restoration persist under treatment [48]. Third, during SIVmac
infections in Chinese (Ch) RMs long-term nonprogression occurs
only in a subset of monkeys [49], cannot be predicted based on in
vitro testing [50] and is associated with persistent viral replication in
tissues [28]. Reagents are not yet fully tested in ChRMs and MHC
characterization is incomplete, as opposed to IndRMs. Finally, a
fraction of SIVmac239-infected Indian RMs with particular MHC
profiles is defined as ‘‘elite-controlling’’ infection [19,20]. Note,
however, that ‘‘EC’’ SIVmac-infected RMs show persistent low
levels of viral replication (102–103 copies/ml) [19]. Moreover, as
for ChRMs, control of infection cannot be predicted before it is
achieved. The advantage of the EC model reported here over the
existing models, is that in SIVagm-infected RMs, a robust acute
viral replication is followed by complete control in all cases,
therefore, to date, this animal model is the only one that can be
used for the study of early events of SIV infection leading to EC
infection and to define the biomarkers that will allow early
identification of the HIV infected patients that have the potential
of controlling infection and the delineation of the parameters of a
successful functional cure of HIV infection (i.e., control of viral
replication in tissues, normalization of apoptosis and immune
activation, seroreversion etc).
One may argue that, since SIVagm infection is cross-species
transmitted to RMs, the proposed model might not be relevant
because control is dependent on host restriction factors. We have
several lines of evidence that the role of host intrinsic immunity
may be peripheral in achieving control of infection in this model:
(i) SIVagm replicated at high levels in RMs during acute infection;
(ii) in vitro data showed persistent high levels of SIVagm.sab
replication (comparable to that of SIVmac) on RM PBMCs; (iii)
the analysis of SIVagm evolution in RMs showed no evidence of
hypermutation that might have been the result of a partial host
restriction through the deaminase system; (iv) the high ds/dn ratios
observed in RMs suggest that SIVagm was under purifying
selection in the postacute phase of SIVagm.sab infection; finally,
(v) Trim5 genotypes of the infected monkeys were not associated
with particular viral replication profiles; (vi) CD8 depletion
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experiments in controllers resulted in rebounds of VL, thus
pointing to an immune control of viral replication.
Another critique to this new animal system may be that it only
models a fraction of controlled HIV infections. LTNPs are a
heterogeneous group of patients, in which different mechanisms
may lead to various levels of viral control [1,51]. Thus, viremic
controllers have residual levels of viral replication. Elite control-
lers, on the other hand, control viral replication to undetectable
levels of plasma viral load, but the majority of ECs have persistent
levels of increased immune activation [52,53], inflammation-
associated vascular dysfunction [54] and declining CD4 counts
over time [52,53]. Only a fraction of EC patients (the ‘‘super-
elites’’), achieve control of immune activation close to baseline
levels, in addition to the control of viral replication. These patients
sustain CD4+ T cell counts and preserved CD8+ T cell function
[Landay, unpublished] and are probably the best examples of
functional cure of HIV infection. Even if these patients represent a
minority of the HIV infected patients, understanding the
mechanisms through which the functional cure of HIV infection
occurs in the absence of antiretroviral therapy is probably the most
important information that can be derived from the study of
controlled HIV/SIV infections for both vaccine development and
HIV eradication efforts. Our new animal system models these
super-elite controllers, which are the most difficult to model in
animal systems and therefore it is a major achievement in the field,
as it can be used to identify the factors driving the infection to elite
controlled status overcoming the most important limitation to the
study of the functional cure, which is that control cannot be
predicted at the time when the virus actively replicate during the
early stages of infection.
We conclude that SIVagm infected RMs represent a valuable
model of super elite controlled infection which can be used to: (i)
examine virologic and immunologic changes during early infection
that may lead to the infection control; (ii) perform invasive studies
facilitating concomitant investigations in a large array of tissues
collected at critical time points of infection; (iii) perform in vivo
manipulation of SIV pathogenesis by selective depletion of
different cellular subsets, or experimental modulation of immune
activation to assess their contribution to the control of VL. Such
experiments have not been and cannot be pursued in studies of
human HIV-1 ECs and thus, this new model addresses an
immediate need in AIDS research: deciphering the mechanisms
and biomarkers of durable and effective control of SIV replication.
Materials and Methods
Ethics statement
The animals were fed and housed according to regulations set
forth by the Guide for the Care and Use of Laboratory Animals [40] and
the Animal Welfare Act. The animal experiments in this study
were approved by the Tulane University Institutional Animal Care
and Use Committee (IACUC).
Animals, infection and samples
Twelve male RM (Macaca mulatta) aged 5–11 years were used.
Animals were intravenously inoculated with plasma equivalent to
150 tissue culture infectious doses (TCID50) of SIVagm.sab92018
[21]. The first group of 6 RMs were followed for up to 6 years p.i.
(the pathogenesis group) to characterize the clinical outcome of
SIVagm infection, the dynamics of viral replication and the impact
of SIVagm infection on the major immune cell populations; the
remaining 6 RMs were serially sacrificed at days 9, 10, 35, 42 and
180 p.i. to assess the dynamics and the levels of tissue replication.
Tissue sampling
Blood was collected from all the animals in the pathogenesis
group at 2 time points preinfection (days -30, -7 p.i.), then at the
time of SIVagm.sab inoculation, twice per week for the first two
weeks p.i., weekly for the next four weeks, every two weeks for the
next two months and then every three months, up to 6 years p.i.
LN biopsies were sampled on days 0, 8, 28, 200, 400, 800, 1200
and 1400 p.i. Intestinal endoscopies (proximal jejunum) consisting
of approximately 10–15, 1–2 mm2 pieces were obtained by
endoscopic guided biopsy were performed on days 0, 8, 14, 21,
28, 42, 72, 84, 100, and then every three months up to 6 years p.i.
Intestinal resections (five to ten cm) were performed at days
preinfection (D-30) and at days 10/42 and 200/600 p.i., as
previously described [31,55]. Additional intestine pieces were
obtained at necropsy. The serially sacrificed RMs were sampled
following the same sampling schedule. Plasma and peripheral
blood mononuclear cells (PBMCs) and mononuclear cells from the
intestine and LNs were isolated as described [10,21]. The serially
sacrificed RMs were euthanized and up to 38 different tissue
samples were collected. Mononuclear cells were separated from all
mucosal and lymphatic tissues as described [10,21], while total
RNA was extracted directly from 100 mg of snap frozen
parenchimatous tissues.
Viral quantification
Plasma VLs were quantified as described [29]. Assay sensitivity
was 100 RNA copies/ml of plasma. For quantification in tissues,
viral RNA was extracted from 56105–106 cells originating from
multiple tissues with RNeasy (Qiagen, Valencia, CA). Snap frozen
tissues were ultrasonicated prior to RNA extraction. VLs were
quantified in blood and tissues as described [21]. Simultaneous
quantification of RNase P (TaqMan Copy Number Reference
Assay RNase P, Applied Biosystems, Carlsbad, CA) normalized
the RNA input from cells [31]. Assay sensitivity was 10 RNA
copies/106 cells.
Analysis of anti-SIVagm.sab immunoglobulin G
responses
An in-house SIVagm.sab-specific primate immunodeficiency
virus enzyme immunoassay was used for the titration of anti-gp41
and anti-V3 antibody titers, as described previously [56], on serial
plasma or serum samples to investigate the dynamics of anti-
SIVagm.sab seroconversion and seroreversion. SIVagm.sab neu-
tralization was measured using a new neutralization assay. An
SIVagm.sab-specific molecularly cloned Envpseudotyped virus
containing full-length gp160 of SIVagm.sab92018 (clone 28) was
prepared as described previously [24]. Neutralization titers were
then measured as 50% reductions in luciferase reporter gene
expression in TZM-bl cells, as reported previously [24].
Antibodies and flow-cytometry
Immunophenotyping of lymphocytes isolated from the blood,
LNs and intestine was performed by using fluorescently conjugat-
ed monoclonal antibodies using a seven-color staining technique.
The samples were run using a LSR-II flow cytometer (Becton
Dickinson) and the data were analyzed using FlowJo (Tree Star,
Inc). The following mAbs were used for flow cytometry: CD3-
Pacific blue (clone no. SP34), CD4-APC (clone no. L200), CCR5-
PE (clone no. 3A9), HLA-DR-APC-Cy7 (clone no. L243), Ki-67-
FITC (clone no. B56) (BD Bioscience), CD95-FITC (clone
no. DX2), CD28-PE-Cy7 (clone no. CD28.2) CD8ab-Texas
Red (clone no. 2ST8.5H7) (Beckman Coulter). All antibodies
were validated and titrated using RM PBMCs. Samples were
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stained for apoptosis using Annexin V: PE Apoptosis Detection kit
I (BD Pharmingen) as per manufacturer instructions. Apoptotic
CD4+ T-cells were defined as Annexin Vpos7AADneg, whereas the
necrotic CD4+ T-cells were defined as Annexin Vpos7AADpos.
CD4+ and CD8+ T-cell percentages were obtained by first gating
on lymphocytes, then on CD3+ T-cells. Memory, activation,
proliferation and apoptosis markers were determined by gating on
lymphocytes, then on CD3+ T cells and finally on CD4+CD3+ or
CD8+CD3+ T cells.
Immunohistochemical staining (IHC) and in situ
hybridization (ISH)
IHC was performed on formalin-fixed, paraffin-embedded
tissues using an avidin-biotin complex horseradish peroxidase
technique (Vectastain Elite ABC kit, Vector Laboratories,
Burlingame, CA) and either mouse monoclonal anti-human
CD4 (NCL-CD4-1F6, Novocastra, Newcastle, UK) or rabbit
polyclonal Activated Caspase-3 (Abcam, Cambridge, MA). For
SIV in situ hybridization (ISH), sections were subjected to high-
temperature unmasking, treated with 0.2 N HCl, and hybridized
overnight at 45uC with either sense or antisense SIVagm
digoxigenin-UTP labeled riboprobe, blocked with normal sheep
serum, incubated with sheep anti-digoxigenin-alkaline phospha-
tase (AP) and incubated with Ferangi blue. SIVagm-infected cell
phenotype was determined after ISH by incubating sections with:
rabbit anti-human CD3 (DAKO, Carpinteria, CA); mouse anti-
human macrophage (HAM56; DAKO); followed by the appro-
priate anti-mouse or anti-rabbit secondary antibodies. ABC
method (Vectastain Elite ABC kit) and amino-ethylcarbazole
(AEC) (DAKO) were also used to detect HAM56 and CD3.
Negative controls included an antisense probe with uninfected
tissues, a sense probe with infected tissues, an antisense probe with
infected tissues and anti-rabbit or anti-mouse secondary antibodies
only.
Microbial translocation was monitored by measuring sCD14
levels, as previously described, using a commercially available
ELISA (R&D systems) [35]. Plasma samples were diluted 5 fold
with endotoxin-free water and then heated to 70uC for 10 minutes
to inactivate plasma proteins. Plasma was diluted 1:300 and assay
was performed in duplicate according to the manufacturer’s
protocol.
Coreceptor usage was determined as described previously [50].
Human osteosarcoma (GHOST) cells expressing CD4 and one of
the following coreceptors were obtained through the NIH AIDS
Research and Reference Program, Division of AIDS, AIAID
contributed by Dan Littman and Vineet KewalRamani: CCR1,
CCR2, CCR3, CCR4, CCR5, CCR8, CXCR4, BOB and Bonzo.
These cells were cultured in complete Dulbecco’s minimal
essential medium containing G418 (5 mg/ml), hygromycin
(1 mg/ml), and puromycin (1 mg/ml). GHOST cells expressing
only CD4 (GHOST-CD4 cells) served as controls; these cells were
cultured in the same medium without puromycin. GHOST cells
(105/ml; 500 ml per well) were maintained in 24-well plates for
24 h. The medium was then removed, and 200 ml of fresh medium
was added, along with a viral inoculum of 10 MOI. On the next
day, residual virus was removed and the cells were washed once
with 1 ml of medium. Then, 750 ml of fresh complete medium
containing the selection antibiotics was added. Productive viral
replication was monitored by measuring SIV P27 Gag antigen in
the culture supernatants on days 0, 2, 4, 6, and 9 by ELISA
(Zeptometrix Corp., Buffalo, NY). In all cases, the amount of
antigen produced in control GHOST-CD4 cells was subtracted
from the amount produced in coreceptor-transfected GHOST-
CD4 cells.
SIVagm.sab92018 env sequencing
Viral evolution in vivo in RMs was investigated as follows:
SIVagm RNA was extracted as described above from serial
plasma samples (collected between days 10–72 pi) and subjected to
PCR amplification. Then, viral RNA was retro-transcribed by
using superscript II RNAse H- Reverse Transcriptase (Invitrogen)
according to the manufacturer’s instructions using primers
EnvASab and EnvBSab [29]. Reverse transcription was done at
25uC for 10 min, 50uC for 30 min and 70uC for 15 min. Resulted
cDNA was amplified by PCR using the proof-reading DNA
polymerases TAKARA Ex Taq (Takara Bio) or Platinum Taq
(Qiagen) following the manufacturer’s instructions. The PCR
conditions consisted of 40 cycles of denaturation (95uC for 10 s), of
hybridization (55uC for 30 s) and elongation (72uC for 1 min). A
seminested PCR was then performed using the same conditions as
for the first round PCR. Primers used were EnvAsab and EnvBsab
for the first round and EnvAsab and NS3asVerTYO (59 GAA
GCC TAA GAA CCC TAG CAC AAA 39) for the seminested
reaction [29]. PCR products were visualized by agarose gel
electrophoresis. PCR products were cloned using the TOPO TA
Cloning Kit (Invitrogen). Plasmids with the correct insert were
sequenced with the universal primer and env sequences were
aligned, translated and analyzed.
TRIM5a sequencing
The TRIM5a genotypes were determined for RM by isolating
genomic DNA from PBMCs and directly sequencing the 526
nucleotides PCR product of the B30.2/SPRY domain of TRIM5a.
The sequence of the primers utilized both for PCR and for the
sequencing reaction are CAGTGCTGACTCCTTTGCTTG for
the forward primer and GCTTCCCTGATGTGATAC for the
reverse primer. The obtained sequences were characterized by
polymorphisms at nucleic acid position 997, 1015–1020, 1022 of
TRIM5a.
Infection of PBMC from different host species
PBMCs were isolated from RM and AGM blood as described
earlier [50]. Freshly isolated PBMCs were stimulated with 10 mg
PHA per ml of medium for 2 days followed by overnight
incubation in IL-2 media. Activated PBMCs (56106) were infected
with SIVagm stocks containing 4,000 pg of P27 at 37uC for 4 h;
cells were then washed extensively to remove any cell-free virus.
Cells were maintained in IL-2 media for 8 weeks. Virus production
in culture supernatants was monitored weekly by SIV P27 antigen
capture assay.
Anti-CD8 Ab treatments
Three SIVagm-infected RM controllers were treated intrave-
nously with cM-T807, a mouse anti-human monoclonal anti-CD8
antibody. Treatments consisted of an initial dose of 50 mg/kg
followed by administration of 10 mg/kg after 6 and 13 days,
respectively. cM-T807 administration was followed by a frequent
sampling of blood (days 0, 4, 7, 10, 14, 21, 28, 35, 42, 56, 72 post
cM-T807 administration) as well as intestinal biopsies (days 0, 7,
14, 21, 28, 42, 72 post cM-T807 administration).
Statistical analysis
Data comparisons were done using two-tailed non-parametric
tests (Mann-Whitney). Correlation analyses among time-varying
variables were done by comparing slopes or using gee with
working independence [57]. Analyses were performed using R (R
Foundation for Statistical Computing, Vienna, Austria).
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Supporting Information
Figure S1 High levels of SIVagm replication in lamina
propria during acute infection of RMs, as determined by
in situ hybridization.
(PDF)
Figure S2 Immunohistochemical assessment of CD4+ T
cell depletion during SIVagm infection of rhesus ma-
caques. Massive CD4+ T cell depletion compared to baseline
levels (D0) was observed after acute SIVagm infection (D42).
(PDF)
Figure S3 Immunophenotyping of the SIVagm infected
cells in rhesus macaques. Combined in situ hybridization for
SIV (blue) and immunohistochemistry (red) for either macrophage
(HAM56) (a) or lymphocyte (CD3) (b) markers demonstrates that
during the acute SIVagm infection of RMs, the majority of the
infected cells are lymphocytes.
(PDF)
Figure S4 Comparison between co-receptor usage of
plasma RNA virus from acutely-infected RMs (DD16,
DG50, day 10 p.i.) and the SIVagm.sab passaged in vitro
(co-culture with RM PBMCs) as measured at day 9 post-
inoculation. Although the in vitro passaged virus appears to be
dual (CCR5 and CXCR4) tropic, similar to parental SIVagm.-
sab92018 (passaged in vitro in AGM PBMCs), the plasma virus is
exclusively CCR5-tropic. Controls: SIVmac239 and SHIV162P3.
Note that, while SIVagm.sab is preferentially using Bonzo,
SIVmac is preferentially using Bob.
(PDF)
Figure S5 Partial gp120 env (678 bp) sequence evolution
in AGM EI42 and RMs P373, V492 and BA38 infected
with SIVagm.sab.92018. Three clones were sequenced from
each similar time points post-infection, as listed. Sequences of the
relapsing virus post-CD8 cell depletion are also shown (in violet).
No significant differences in viral evolution were noted between
AGM and RMs.
(PDF)
Acknowledgments
We thank Drs. Andrew Lackner, Preston Marx, Marion Ratterree and
Rudolf Bohm and for helpful discussion and Division of Veterinary
Medicine of Tulane National Primate Research Center for animal care.
This work represents the opinions of the authors and not necessarily the
National Institutes of Health or the Department of Health and Human
Services.
Author Contributions
Conceived and designed the experiments: CA IP. Performed the
experiments: Animal work: TG RG DM. Cell separation and staining:
DM TG. Viral load quantification: DM RG JK. Trim genotyping: BFK.
Serology: TG RG DCM. Analyzed the data: IP CA RMR RSV.
Contributed reagents/materials/analysis tools: RSV RMR DCM. Wrote
the paper: CA IP.
References
1. Deeks SG, Walker BD (2007) Human immunodeficiency virus controllers:
mechanisms of durable virus control in the absence of antiretroviral therapy.
Immunity 27: 406–416.
2. Baker BM, Block BL, Rothchild AC, Walker BD (2009) Elite control of HIV
infection: implications for vaccine design. Expert Opin Biol Ther 9: 55–69.
3. Hirsch VM, Johnson PR (1994) Pathogenic diversity of simian immunodefi-
ciency viruses. Virus Res 32: 183–203.
4. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid
turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature
373: 123–126.
5. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral
dynamics in human immunodeficiency virus type 1 infection. Nature 373:
117–122.
6. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, et al. (1996)
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.
Science 272: 1167–1170.
7. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ (2006) Pathogenesis of
HIV infection: what the virus spares is as important as what it destroys. Nat Med
12: 289–295.
8. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. (2004) CD4+
T cell depletion during all stages of HIV disease occurs predominantly in the
gastrointestinal tract. J Exp Med 200: 749–759.
9. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, et al. (2004)
Primary HIV-1 infection is associated with preferential depletion of CD4+ T
lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200: 761–770.
10. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, et al. (1998)
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral
replication in SIV infection. Science 280: 427–431.
11. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, et al. (1999)
Shorter survival in advanced human immunodeficiency virus type 1 infection is
more closely associated with T lymphocyte activation than with plasma virus
burden or virus chemokine coreceptor usage. J Infect Dis 179: 859–870.
12. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. (1994) Temporal
association of cellular immune responses with the initial control of viremia in
primary human immunodeficiency virus type 1 syndrome. J Virol 68:
4650–4655.
13. Siliciano R (2000) Can antiretroviral therapy ever be stopped? AIDS Read 10:
224–229.
14. Richman DD (2001) HIV chemotherapy. Nature 410: 995–1001.
15. Desrosiers RC (2004) Prospects for an AIDS vaccine. Nat Med 10: 221–223.
16. Sekaly RP (2008) The failed HIV Merck vaccine study: a step back or a
launching point for future vaccine development? J Exp Med 205: 7–12.
17. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV
nonprogressors preferentially maintain highly functional HIV-specific CD8+ T
cells. Blood 107: 4781–4789.
18. Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, et al. (2007) Fully
differentiated HIV-1 specific CD8+ T effector cells are more frequently
detectable in controlled than in progressive HIV-1 infection. PLoS ONE 2:
e321.
19. Loffredo JT, Maxwell J, Qi Y, Glidden CE, Borchardt GJ, et al. (2007) Mamu-
B*08-positive Macaques Control Simian Immunodeficiency Virus Replication.
J Virol 81: 8827–8832.
20. Yant LJ, Friedrich TC, Johnson RC, May GE, Maness NJ, et al. (2006) The
high-frequency major histocompatibility complex class I allele Mamu-B*17 is
associated with control of simian immunodeficiency virus SIVmac239
replication. J Virol 80: 5074–5077.
21. Pandrea I, Apetrei C, Dufour J, Dillon N, Barbercheck J, et al. (2006) Simian
immunodeficiency virus (SIV) SIVagm.sab infection of Caribbean African green
monkeys: New model of the study of SIV pathogenesis in natural hosts. J Virol
80: 4858–4867.
22. Pandrea I, Silvestri G, Onanga R, Veazey RS, Marx PA, et al. (2006) Simian
immunodeficiency viruses replication dynamics in African non-human primate
hosts: common patterns and species-specific differences. J Med Primatol 35:
194–201.
23. Pandrea I, Onanga R, Kornfeld C, Rouquet P, Bourry O, et al. (2003) High
levels of SIVmnd-1 replication in chronically infected Mandrillus sphinx. Virology
317: 119–127.
24. Gaufin T, Pattison M, Gautam R, Stoulig C, Dufour J, et al. (2009) Effect of B
cell depletion on viral replication and clinical outcome of SIV infection in a
natural host. J Virol 83: 10347–10357.
25. Picker LJ, Hagen SI, Lum R, Reed-Inderbitzin EF, Daly LM, et al. (2004)
Insufficient production and tissue delivery of CD4+ memory T cells in rapidly
progressive simian immunodeficiency virus infection. J Exp Med 200:
1299–1314.
26. Pawar SN, Mattila JT, Sturgeon TJ, Lin PL, Narayan O, et al. (2008)
Comparison of the effects of pathogenic simian human immunodeficiency virus
strains SHIV-89.6P and SHIV-KU2 in cynomolgus macaques. AIDS Res Hum
Retroviruses 24: 643–654.
27. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, et al. Profound
early control of highly pathogenic SIV by an effector memory T-cell vaccine.
Nature 473: 523–527.
28. Ling B, Mohan M, Lackner AA, Green LC, Marx PA, et al. (2010) The large
intestine as a major reservoir for simian immunodeficiency virus in macaques
with long-term, nonprogressing infection. J Infect Dis 202: 1846–1854.
29. Pandrea I, Kornfeld C, Ploquin MJ-I, Apetrei C, Faye A, et al. (2005) Impact of
viral factors on very early in vivo replication profiles in SIVagm-infected African
green monkeys. J Virol 79: 6249–6259.
30. Gnanadurai CW, Pandrea I, Parrish NF, Kraus MH, Learn GH, et al. (2010)
Genetic identity and biological phenotype of a Transmitted/Founder virus
Animal Model for Elite Controlled SIV Infection
PLoS Pathogens | www.plospathogens.org 14 August 2011 | Volume 7 | Issue 8 | e1002170
representative of non-pathogenic simian immunodeficiency virus infection in
African green monkeys. J Virol 84: 12245–12254.
31. Pandrea I, Gautam R, Ribeiro R, Brenchley JM, Butler IF, et al. (2007) Acute
loss of intestinal CD4+ T cells is not predictive of SIV virulence. J Immunol 179:
3035–3046.
32. VandeWoude S, Apetrei C (2006) Going wild: Lessons from T-lymphotropic
naturally occurring lentiviruses. Clin Microbiol Rev 19: 728–762.
33. Pandrea I, Ribeiro RM, Gautam R, Gaufin T, Pattison M, et al. (2008) Simian
immunodeficiency virus SIVagm dynamics in African green monkeys. J Virol
82: 3713–3724.
34. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, et al. (2005) Peak SIV replication in
resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature
434: 1148–1152.
35. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006)
Microbial translocation is a cause of systemic immune activation in chronic HIV
infection. Nature Medicine 12: 1365–1371.
36. Poss M, Ross HA, Painter SL, Holley DC, Terwee JA, et al. (2006) Feline
lentivirus evolution in cross-species infection reveals extensive G-to-A mutation
and selection on key residues in the viral polymerase. J Virol 80: 2728–2737.
37. Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, et al. TRIM5
suppresses cross-species transmission of a primate immunodeficiency virus and
selects for emergence of resistant variants in the new species. PLoS Biol 8:
e1000462.
38. Muller MC, Barre-Sinoussi F (2003) SIVagm: genetic and biological features
associated with replication. Front Biosci 8: D1170–1185.
39. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, et al. (1999)
Control of viremia in simian immunodeficiency virus infection by CD8+
lymphocytes. Science 283: 857–860.
40. Gautam R, Gaufin T, Butler I, Gautam A, Barnes M, et al. (2009) SIVrcm, a
unique CCR2-tropic virus, selectively depletes memory CD4+ T cells in pigtailed
macaques through rapid coreceptor expansion in vivo. J Virol 83: 7894–7908.
41. Apetrei C, Gaufin T, Gautam R, Vinton C, Hirsch VM, et al. (2010) Pattern of
SIVagm infection in patas monkeys suggests that host adaptation to SIV
infection may result in resistance to infection and virus extinction. J Infect Dis
202 Suppl 3: S371–376.
42. Hatano H, Delwart EL, Norris PJ, Lee TH, Neilands TB, et al. Evidence of
persistent low-level viremia in long-term HAART-suppressed, HIV-infected
individuals. AIDS 24: 2535–2539.
43. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, et al. (2008) Low-
level viremia persists for at least 7 years in patients on suppressive antiretroviral
therapy. Proc Natl Acad Sci U S A 105: 3879–3884.
44. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, et al. (2009)
Incomplete peripheral CD4+ cell count restoration in HIV-infected patients
receiving long-term antiretroviral treatment. Clin Infect Dis 48: 787–794.
45. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, et al. Evidence for
the cure of HIV infection by CCR5 Delta32/Delta32 stem cell transplantation.
Blood 117: 2791–2799.
46. Desrosiers RC, Lifson JD, Gibbs JS, Czajak SC, Howe AY, et al. (1998)
Identification of highly attenuated mutants of simian immunodeficiency virus.
J Virol 72: 1431–1437.
47. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, et al. (2007) Isolation
and characterization of replication-competent human immunodeficiency virus
type 1 from a subset of elite suppressors. J Virol 81: 2508–2518.
48. Carruth LM, Zink MC, Tarwater PM, Miller MD, Li M, et al. (2005) SIV-
specific T lymphocyte responses in PBMC and lymphoid tissues of SIV-infected
pigtailed macaques during suppressive combination antiretroviral therapy. J Med
Primatol 34: 109–121.
49. Ling B, Veazey RS, Hart M, Lackner AA, Kuroda M, et al. (2007) Early
restoration of mucosal CD4 memory CCR5 T cells in the gut of SIV-infected
rhesus predicts long term non-progression. Aids 21: 2377–2385.
50. Gautam R, Carter AC, Katz N, Butler IF, Barnes M, et al. (2007) In vitro
characterization of primary SIVsmm isolates belonging to different lineages. In
vitro growth on rhesus macaque cells is not predictive for in vivo replication in
rhesus macaques. Virology 362: 257–270.
51. Hunt PW (2009) Natural control of HIV-1 replication and long-term
nonprogression: overlapping but distinct phenotypes. J Infect Dis 200:
1636–1638.
52. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, et al. (2008)
Relationship between T cell activation and CD4+ T cell count in HIV-
seropositive individuals with undetectable plasma HIV RNA levels in the
absence of therapy. J Infect Dis 197: 126–133.
53. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, et al. (2009)
The challenge of finding a cure for HIV infection. Science 323: 1304–1307.
54. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, et al. (2009) Role of viral
replication, antiretroviral therapy, and immunodeficiency in HIV-associated
atherosclerosis. AIDS 23: 1059–1067.
55. Gaufin T, Gautam R, Kasheta M, Ribeiro RM, Ribka E, et al. (2009) Limited
ability of humoral immune responses in control of viremia during infection with
SIVsmmD215 strain. Blood 113: 4250–4261.
56. Simon F, Souquiere S, Damond F, Kfutwah A, Makuwa M, et al. (2001)
Synthetic peptide strategy for the detection of and discrimination among highly
divergent primate lentiviruses. AIDS Res Hum Retroviruses 17: 937–952.
57. Diggle PJ, Heagerty P, Laing K-Y, Zeger SL (2002) Analysis of longitudinal
data. Oxford, UK: Oxford University Press.
Animal Model for Elite Controlled SIV Infection
PLoS Pathogens | www.plospathogens.org 15 August 2011 | Volume 7 | Issue 8 | e1002170
